NuVision Biotherapies

NuVision Biotherapies is redefining eye care with Omnigen®, an innovative amniotic membrane treatment that improves outcomes for patients with ocular disease and injury. Spun out from the University of Nottingham’s School of Medicine in 2014, the company is committed to delivering sight-saving amniotic membrane technologies worldwide, enhancing quality of life while promoting the use of a sustainable, upcycled material. 

Unlike traditional treatments that require surgical settings, Omnigen®, produced using NuVision’s patented Tereo® technology, is a room-temperature, ready-to-use product. Applied like a plaster and secured with the OmniLenz® contact lens, it brings the proven healing benefits of amniotic membrane into an outpatient environment, reducing cost and complexity and improving patient access. 

Backed by strong clinical evidence – including randomised controlled trial data and recognition in international dry eye guidelines – Omnigen® is now used in 150 NHS centres and approved in 10 international territories.